NEW YORK, Dec. 8, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
IntroductionAcross the branded prescription pharmaceutical market monoclonal antibodies (MAbs) are forecast to be the strongest performing molecule type, delivering a forecast six year compound annual growth rate of 9.5% over 2009-15, outpacing the growth rates of small molecules, therapeutic proteins and vaccines. As a result, there is a strong correlation between a strong MAbs portfolio and overall company
Features and benefitsStrategic dynamics within the sector are broken down by product, company, geography, therapy area, technology type and target.
The outlook for the sector is compared with other sectors of the pharmaceutical industry: small molecules, therapeutic proteins and vaccines.
The impact of biosimilars on future MAb sales growth is evaluated and compared with small molecule brand sales following genericization
While Datamonitor believes biosimilar MAbs will make it onto the major markets, the rate of sales erosion of such a biosimilar MAb will be far less than that experienced by a small molecule upon generic entry.
Your key questions answeredAssess the outlook for the monoclonal antibodies sector through to 2015
Evaluate the impact of monoclonal antibody on company performances across the PharmaVitae universe
Appraise the technological developments being made in the sector and see where monoclonal antibody pipelines are being focused
TABLE OF CONTENTSABOUT DATAMONITOR HEALTHCARE 2
Copyright©2010 PR Newswire.
All rights reserved